Immunobullous Disease Antibody Panel

Clinical Use

Use

The Immunobullous Disease Antibody Panel is used for initial comprehensive testing to aid in the diagnosis and differentiation of skin and mucosal disorders that present with blistering, eczema, erosions, pruritus, and/or urticaria. It assesses suspected epithelial antibody-associated immunobullous diseases such as pemphigoid, pemphigus, and their variants that are not clinically distinguishable. The panel is especially useful when concurrent Direct Immunofluorescence with Tissue Biopsy indicates such disorders, or in cases due as potential side effects of immune checkpoint inhibitor (anti-PD-1, anti-PD-L1) therapy.

Special Instructions

Not provided.

Limitations

Negative results for IgG, IgG4, and IgA basement membrane zone antibodies do not rule out diseases such as bullous pemphigoid, epidermolysis bullosa acquisita, and linear IgA bullous dermatosis, as antibodies may not be detectable in all cases. Additionally, negative ELISA results for antibodies like BP180, BP230, and type VII collagen may miss some cases due to variability in disease presentation and antibody expression.

Test Details

New York Approved

Methodology

Immunoassay (Semi-Quantitative ELISA)

Biomarkers

2 components

Indirect Immunofluorescence (IIF) • Indirect ImmunofluorescenceEnzyme-Linked Immunosorbent Assay (ELISA) • ELISA

Result Turnaround Time

3-9 days

Specimen

Serum

Volume

2 mL

Minimum Volume

0.5 mL

Container

ARUP standard transport tube

Collection Instructions

Collect in a plain red or serum separator tube (SST), then transfer 2 mL serum to a transport tube.

Storage Instructions

Specimens should be stored refrigerated unless shipping promptly (within 2 hours). Transport at ambient temperature to arrive within 7 days. If storage is 7-14 days until received, store and ship refrigerated. Store and ship frozen if more than 14 days.